(HOW) IT WORKS

FOR FROWN LINES

Jeuveau is a popular wrinkle treatment that is injected in the muscles that cause frown lines to form.
Jeuveau prevents your nerves from telling your muscles to flex or contract. This process smooths the appearance of “dynamic” frown lines — like the ones from years of frowning at your phone.
The effects can last for up to 4 months while the muscle activity gradually returns. 
Evolus ModelEvolus Model
Evolus Model

DOES Jeuveau work as well as Botox® Cosmetic?

Jeuveau was studied against Botox® Cosmetic in the largest head-to-head phase III study in frown lines to see whether Jeuveau was inferior to a legacy brand. This study evaluated 540 adults with moderate to severe frown lines and showed that Jeuveau is not inferior to Botox® Cosmetic.*†
At Day 30
BOTOX® Cosmetic
82.8%
of people studied saw improvement (n=244)
Two Jeuveau vials
At Day 30
Jeuveau
87.2%
of people studied saw improvement (n=235)
*A non-inferiority study is conducted to show that the effect of a treatment is not worse than the original treatment.
† Rzany B. A multicenter, randomized, double-blind, placebo-controlled, single-dose, phase III, non-inferiority study comparing prabotulinumtoxinA and onabotulinumtoxinA for the treatment of moderate to severe glabellar lines in adult patients. About 50% of patients begin showing improvement after two days (≥1-grade improvement by physician assessment).
Botox® Cosmetic is a registered trademark of Allergan, Inc.

HOW WELL DOES Jeuveau work?

Jeuveau is well-studied in five clinical trials
- with more than 2100 patients
30 days after treatment, the majority of people injected with
Jeuveau had either*
  • No frown lines.
  • Barely noticeable frown lines.
We also ran the largest head-to-head study** looking at Jeuveau vs. Botox® Cosmetic. We're confident in our product so you can be, too. 
If precise, natural-looking results are what you’re looking for from a neurotoxin, ask for Jeuveau by Evolus.
*In two U.S. clinical studies, 68% and 70% of Jeuveau patients with moderate to severe frown lines had a 2-grade or better physician- and patient-rated improvement (none or mild frown lines) at Day 30.
**A non-inferiority study is conducted to show that the effect of a treatment is not worse than the original treatment.
Botox® Cosmetic is a registered trademark of Allergan, Inc.
Evolus Model
WHAT DO INJECTORS SAY ABOUT Jeuveau
Hear from dermatologists, plastic surgeons, nurses and other licensedprofessionals who trust & recommend Jeuveau

"If you're someone who’s concerned about looking frozen, we recommend Jeuveau. It kicks in fast and allows for some expression while temporarily smoothing frown lines."

Heather Hutnick

Revive Med Spa

“When I’m using a neuromodulator, I want one that's proven predictable in its outcome, and natural in its appearance. I get that with Jeuveau, which is very soft and natural appearing. My patients love the results, so it’s one of my go-to's, likely my first!
I love it.”

Dr. Todd Rozycki, MD, FAAD, FASDS

South Mend Clinic Dermatology

“I love Jeuveau because my clients love its quick onset and the duration of the product. Many clients notice quick onset and their results often last up to four months.”

Pam Chaney

Founder, Owner & Director of Pam Chaney Aesthetics

“We like to use Jeuveau for the natural look that it offers and because of the quick onset.”

Dr. John Layke & Dr. Payman Danielpour

Beverly Hills Plastic Surgery Group

“As an injector, I love Jeuveau because of the precision it allows me, the quick onset it has with my patients, and the long duration.”

Erin Courtway

Owner, Nurse Practitioner & Injector, Prism Aesthetics

Jeuveau NEAR ME
Right arrow
READY TO SEE SMOOTHER FROWN LINES?
Day 0 & Day 30
Day 2
Day 30
Day 120
Day 0 & Day 30
Day 2
Day 30
Day 120
Soo Youn
Soo Youn
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Soo Youn
Soo Youn
Soo Youn
Soo Youn
Soo Youn
Soo Youn
Soo YounSoo Youn
David
David
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
David
David
David
David
David
David
DavidDavid
Arielle
Arielle
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Arielle
Arielle
Arielle
Arielle
Arielle
Arielle
ArielleArielle
Sarah
Sarah
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Sarah
Sarah
Sarah
Sarah
Sarah
Sarah
SarahSarah
Tajah
Tajah
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Tajah
Tajah
Tajah
Tajah
Tajah
Tajah
TajahTajah
Lisa
Lisa
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Lisa
Lisa
Lisa
Lisa
Lisa
Lisa
LisaLisa
Tia
Tia
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Tia
Tia
Tia
Tia
Tia
Tia
TiaTia
Shai
Shai
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Shai
Shai
Shai
Shai
Shai
Shai
ShaiShai
Tugba
Tugba
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Tugba
Tugba
Tugba
Tugba
Tugba
Tugba
TugbaTugba
Josephine
Josephine
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Josephine
Josephine
Josephine
Josephine
Josephine
Josephine
JosephineJosephine
Soo Youn
David
Arielle
Sarah
Tajah
Lisa
Tia
Shai
Tugba
Josephine
See More Results
Right arrow
At maximum frown. Actual patient. Results may vary.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3

In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3

In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3

In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3

In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3

In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3

In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3

In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3

In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3

In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3

In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3

In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3

In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3

In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3

In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3

In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3

In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3

In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3

In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3

In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3

In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.

Soo Youn
David
Arielle
Sarah
Tajah
Lisa
Tia
Shai
Tugba
Josephine
See More Results
Right arrow
At maximum frown. Jeuveau® patient. Individual results may vary.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3

In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3

In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3

In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3

In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3

In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3

In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3

In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3

In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3

In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3

In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3

In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3

In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3

In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3

In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3

In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3

In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3

In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3

In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3

In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3

In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.

FREQUENTLY ASKED QUESTIONS

(Apart from “How soon can I book?”)
Where can I find Jeuveau Prescribing Information?
Up arrow

Here is our Prescribing Information, including our Boxed Warning. This is also enclosed in every package of Jeuveau to ensure healthcare providers have immediate access and can answer any questions or concerns you may have about treatment and find the most important things you need to know about Jeuveau.

Where can I find the Jeuveau Medication Guide?
Up arrow

Here is our Medication Guide, where you will find the most important things you need to know about Jeuveau and getting treated with Jeuveau.

What exactly is Jeuveau?
Up arrow

You know those pesky little wrinkles between your eyebrows that won’t go away? Well, they're called glabellar lines, also referred to as "frown lines" or "elevens." Jeuveau is a prescription injectable treatment that works to temporarily improve the appearance of moderate to severe frown lines in adults.

How does Jeuveau work?
Up arrow

When injected, Jeuveau temporarily prevents your nerves from telling your facial muscles to flex. The result? In clinical trials, Jeuveau was shown to temporarily improve the appearance of moderate to severe frown lines.

What are the results with Jeuveau?
Up arrow

In clinical trials, Jeuveau was shown to temporarily improve the appearance of moderate to severe frown lines. In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30. But that's not all. In a study conducted in Europe and Canada, 54% of patients had visible results as early as 2 days after treatment.* And at 5 months after treatment, 38% of patients had visible results with Jeuveau**

*54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint). In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 8% and 17% for placebo (exploratory endpoint). Results based on a 1-grade improvement may not be clinically meaningful.

*38% of Jeuveau patients had a ≥1-grade improvement in frown lines at 5 months based on physician assessment compared to 8% for placebo (secondary endpoint). In US studies, almost 5% of patients had a ≥2-grade improvement in frown lines at 5 months based on both patient and physician assessments compared to 0% for placebo (secondary endpoint). Results after day 30 or based on a 1-grade improvement may not be clinically meaningful.

What’s it like before & after treatment?
Up arrow

If it’s your first time getting a treatment, you may be a little nervous and that’s okay! Localized pain, infection, inflammation, tenderness, swelling, erythema, and/or bleeding/bruising may be associated with the injection. For specific instructions on what to do before and after your treatment, please follow the instructions as given to you by your doctor or healthcare provider.

What should I tell my doctor before getting treatment with Jeuveau?
Up arrow

Tell your healthcare provider about all your muscle or nerve conditions, such as ALS or Lou Gehrig’s disease, Myasthenia gravis, or Lambert-Eaton syndrome, as you may be at increased risk of serious side effects including difficulty swallowing and difficulty breathing from typical doses of Jeuveau.

Tell your healthcare provider about all your medical conditions, including: any side effects from botulinum toxin products, including dry eye; breathing, swallowing, bleeding, or heart problems; plans to have surgery; weakness of forehead muscles; drooping eyelids; have had surgery on your face; are pregnant or breastfeeding or plan to become pregnant or breastfeed (it is not known if Jeuveau can harm your unborn baby or passes into breast milk).

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Using Jeuveau with certain other medicines may cause serious side effects. Do not start any new medicines until you have told your healthcare provider that you have received Jeuveau in the past.

Especially tell your healthcare provider if you: have received any other botulinum toxin product in the past and the last 4 months, and exactly which product you received (such as BOTOX, BOTOX Cosmetic, MYOBLOC, DYSPORT, XEOMIN, or DAXXIFY).

What are the possible side effects of Jeuveau?
Up arrow

No serious or drug-related adverse events were observed in the Jeuveau clinical studies.

Jeuveau may cause serious side effects that can be life threatening. Get medical help right away if you have any of these problems any time (hours to weeks) after injection of Jeuveau:

  • Problems swallowing, speaking, or breathing, due to weakening of associated muscles, can be severe and result in loss of life. You are at the highest risk if these problems are pre-existing before injection. Swallowing problems may last for several months.
  • Spread of toxin effects. The effect of botulinum toxin may affect areas away from the injection site and cause serious symptoms including: loss of strength and all-over muscle weakness, double vision, blurred vision and drooping eyelids, hoarseness or change or loss of voice, trouble saying words clearly, loss of bladder control, trouble breathing, trouble swallowing.

Jeuveau can cause other serious side effects including:

  • Allergic reactions such as itching, rash, red itchy welts, wheezing, trouble breathing, asthma symptoms, or dizziness or feeling faint. Tell your healthcare provider or get emergency medical help right away if you develop wheezing or trouble breathing, or if you feel dizzy or faint.
  • Heart problems. Irregular heartbeat and heart attack that have caused death, have happened in some people who received botulinum toxin products.
  • Eye problems such as dry eye, reduced blinking, and corneal problems. Tell your healthcare provider if you develop eye pain or irritation, sensitivity to light, or changes in your vision.

The most common side effects of Jeuveau include headache, eyelid drooping, upper respiratory infection, and increased white blood cell count.

These are not all the possible side effects of Jeuveau. Call your doctor for medical advice about side effects. You may report side effects to FDA at www.fda.gov/medwatch or 1-800-FDA-1088.

Where can I find Jeuveau?
Up arrow

We thought you might ask that. Jeuveau is available at select practices throughout the country.

Jeuveau is a prescription treatment injected into muscles to temporarily improve the look of moderate to severe frown lines between the eyebrows in adults.
1. Jeuveau (package insert). Newport Beach, CA :Evolus, Inc. 2020
2. Rzany B. A multicenter, randomized, double-blind, placebo-controlled, single-dose, phase III, non-inferiority study comparing prabotulinumtoxinA and onabotulinumtoxinA for the treatment of moderate to severe glabellar lines in adult patients. About 50% of patients begin showing improvement after two days (≥1-grade improvement by physician assessment). Aesthet Surg J. 2020;40(4):413-429.
3. Beer K. Efficacy and safety of prabotulinumtoxinA for the treatment of glabellar lines in adult subjects: results from identical phase III studies. Most patients (~69%) achieve complete results by day 30 (≥2-grade improvement by physician and patient assessments). Dermatol Surg. 2019;45(11):1381-1393
4. Patient survey data collected 30 days after treatment (n=9151); slightly to extremely satisfied on a 5-point rating scale. Jeuveau Experience Treatment (J.E.T.) Interim Data Report, 12/16/2019; Evolus, Inc.